Back to journals
Academic Journal

Journal of Clinical Psychiatry

20 Papers Indexed in Blossom

Published Papers

Paywallindividual

Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder

This one-year observational follow-up study (n=66) examined the long-term outcomes of psilocybin (25 mg, 10 mg, 1 mg; COMP360) in treatment-resistant depression (TRD). Median time to depressive relapse was longest in the 25 mg group (92 days) compared to 10 mg (83 days) and 1 mg (62 days), with most participants relapsing by week 12. A post hoc analysis of those entering the follow-up study (n=58) found a more pronounced difference, with the 25 mg group maintaining benefits for 189 days. Adverse events were minimal, with one case of mild suicidal ideation in the 1 mg group.

Published
Journal
Journal of Clinical Psychiatry
Authors
Goodwin, G. M., Nowakowska, A., Atli, M., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Marwood, L., Shabir, Z., Mistry, S., Stansfield, S. C., Teoh, E., Tsai, J., Young, M. B., Malievskaia, E.
Open Accessindividual

Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression

This secondary analysis (n=321) of the ESCAPE-TRD trial compared work productivity loss (WPL) and related costs in patients with treatment-resistant depression (TRD) receiving esketamine nasal spray (56mg or 84mg) versus quetiapine (atypical antipsychotic) extended release, both combined with an oral antidepressant. By week 8, WPL decreased by 30.3% with esketamine and 17.3% with quetiapine, leading to a cost savings difference of $156 per week. By week 32, WPL reductions were 45.3% (esketamine) and 32.5% (quetiapine), with a weekly cost savings difference of $153.

Published
Journal
Journal of Clinical Psychiatry
Authors
Clemens, K., Pmhnp-Bc, A., Teeple, D., Zhdanava, M., Shah, A., Joshi, K., Buyze, J., Pilon, D., Bowrey, H. E., Godinov, Y.
Paywallindividual

Barriers to Esketamine Nasal Spray Treatment Among Adults With Treatment-Resistant Depression

This retrospective observational cohort study (n=966 esketamine initiators, n=39,219 controls) examines factors influencing esketamine initiation and continuation for treatment-resistant depression (TRD). Initiators resided closer to treatment centres, with initiation rates decreasing significantly with distance. Factors associated with increased initiation included posttraumatic stress disorder, suicidal ideation, and male sex, while Medicaid, substance use disorder, older age, and greater distance were associated with lower initiation rates.

Published
Journal
Journal of Clinical Psychiatry
Authors
Joshi, K., Liberman, J. N., Parab, P., Darer, J. D., Harding, L.
Open Accessindividual

Microdosing psychedelics has no impact on cognitive function in naturalistic settings

In a within-subjects naturalistic study of 17 people repeatedly tested with the CNSVS battery, psychedelic microdosing produced no measurable improvement or impairment across processing speed, attention, executive function, working memory or memory. The authors suggest perceived benefits of microdosing are psychological rather than neurocognitive and note that remote cognitive batteries are feasible for longitudinal cross‑cultural research.

Published
Journal
Journal of Clinical Psychiatry
Authors
Dinkelacker, J., Pop, I.
Paywallmeta

Control Conditions in Randomized Trials of Psychedelics: An ACTTION Systematic Review

This systematic review (2023, s=86) of psychedelic RCTs (up to May 2020) finds that for placebo, 61% used an inert control, 20% active comparators (e.g. niacin), 15% both, and 4% a lower psychedelic dose. Of the 21 therapeutic trials, only 3 (14%) compared different amounts of therapy. Most studies were blinded, but less than 20% tested blinding (generally poor).

Published
Journal
Journal of Clinical Psychiatry
Authors
Nayak, S., Bradley, M. K., Kleykamp, B. A., Strain, E. C., Dworkin, R. H., Johnson, M. W.
Paywallmeta

Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis

This meta-analysis (s=8, n=1437) compared the effect of intranasal esketamine to placebo (both in combination with standard antidepressants) as a treatment for major depressive disorder (MDD). It was found that intranasal esketamine, in combination with the standard treatment, did effectively reduce depression severity when compared to the placebo, with higher doses having a longer-lasting effect.

Published
Journal
Journal of Clinical Psychiatry
Authors
Hock, R. S., Feeney, A., Iovieno, N., Murrough, J. W., Sanjay, ;., Mathew, J., Iosifescu, D. V., Fava, M., Jha, M. K., Papakostas, G. I.

Quick Facts

Papers Indexed
20
h-Index
236
Open Access
No
Publisher
Physicians Postgraduate Press
Country
United States
Website
Visit